CN103961392A - Traditional Tibetan medicine for treating diabetes - Google Patents
Traditional Tibetan medicine for treating diabetes Download PDFInfo
- Publication number
- CN103961392A CN103961392A CN201410222945.8A CN201410222945A CN103961392A CN 103961392 A CN103961392 A CN 103961392A CN 201410222945 A CN201410222945 A CN 201410222945A CN 103961392 A CN103961392 A CN 103961392A
- Authority
- CN
- China
- Prior art keywords
- tibetan medicine
- group
- fructus
- active component
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 93
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 30
- 239000000843 powder Substances 0.000 claims description 36
- 229940079593 drug Drugs 0.000 claims description 20
- 239000009609 fructus phyllanthi Substances 0.000 claims description 15
- 239000008187 granular material Substances 0.000 claims description 7
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 19
- 238000002360 preparation method Methods 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 12
- 235000013399 edible fruits Nutrition 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000035922 thirst Effects 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 238000010791 quenching Methods 0.000 abstract description 4
- 208000004880 Polyuria Diseases 0.000 abstract description 3
- 210000003734 kidney Anatomy 0.000 abstract description 3
- 230000000171 quenching effect Effects 0.000 abstract description 3
- 244000018436 Coriandrum sativum Species 0.000 abstract description 2
- 244000119298 Emblica officinalis Species 0.000 abstract description 2
- 235000015489 Emblica officinalis Nutrition 0.000 abstract description 2
- 240000003065 Malva verticillata Species 0.000 abstract description 2
- 235000002384 Malva verticillata Nutrition 0.000 abstract description 2
- 206010003549 asthenia Diseases 0.000 abstract description 2
- 230000007812 deficiency Effects 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 235000002787 Coriandrum sativum Nutrition 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010051602 Laziness Diseases 0.000 abstract 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 abstract 1
- 206010039424 Salivary hypersecretion Diseases 0.000 abstract 1
- 239000001387 apium graveolens Substances 0.000 abstract 1
- 230000035622 drinking Effects 0.000 abstract 1
- 206010026820 marasmus Diseases 0.000 abstract 1
- 208000022530 polyphagia Diseases 0.000 abstract 1
- 208000026451 salivation Diseases 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 54
- 239000008280 blood Substances 0.000 description 53
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 45
- 239000008103 glucose Substances 0.000 description 45
- 238000011282 treatment Methods 0.000 description 39
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 7
- 229960001052 streptozocin Drugs 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000003345 hyperglycaemic effect Effects 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 210000002700 urine Anatomy 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 229960004580 glibenclamide Drugs 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 4
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 2
- 241000125183 Crithmum maritimum Species 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000002764 Apium graveolens Nutrition 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 241000219071 Malvaceae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- -1 muscle Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Tibetan medicine for treating diabetes, which is prepared from an active component or active component and pharmaceutically acceptable auxiliary materials, wherein the active component is prepared from cluster mallow fruit, coriander fruit, celery seed and emblic leafflower fruit according to certain parts by weight. The traditional Tibetan medicine can be prepared into any common oral preparation formulation. The traditional Tibetan medicine has the effects of nourishing the kidney, nourishing yin, invigorating qi, promoting salivation and quenching thirst. The traditional Tibetan medicine is used for diabetes caused by deficiency of both qi and yin, which has the symptoms of thirst, desire for drinking, diuresis, polyphagia, marasmus, asthenia, short breath, laziness to speak and the like.
Description
Technical field
The present invention relates to a kind of Tibetan medicine for the treatment of diabetes, belong to Tibetan medicine field.
Background technology
Diabetes are a kind of common metabolism endocrinopathyes, and World Health Organization (WHO) is classified as one of ten large difficult disease.Sickness rate is high, and has the trend rising year by year; According to New York Times, a current research demonstration, the diabetes prevalence of China occupy first place, the world, but also is continuing deterioration.The aforementioned current research that is published in " JAMA " shows, the diabetes prevalence of China has just exceeded the U.S.: 11.6% Chinese adult suffers from this disease, and the U.S. is 11.3%.1980, the diabetes prevalence of China was less than 1%.Diabetes mellitus in China patient total number of persons reaches 1.14 hundred million, rises 2,200 ten thousand than estimative figure in 2007, that is to say, the diabetics in the whole world about 1/3rd is all in China.More allow people's worry, this research is tested 9.9 ten thousand people nearly, and the people's blood glucose that finds that there is half has reached " prediabetes " level.Research is pointed out: " China is one of country that Asia diabetes prevalence is the highest at present, be also in the world the maximum country of the absolute number of diabetics ".
Modern medicine there will be many untoward reaction in various degree in the process for the treatment of diabetes, and Chinese medicine is slow to the therapeutical effect of diabetes, but belong to the category that effects a permanent cure, when blood glucose declines, body constitution is synchronously strengthened, chronic complicating diseases is had to good preventive and therapeutic action.
Tibetan medicine's theory is thought: trouble diabetes are relevant to " three categories of etiologic factors " imbalance of self body.Under normal circumstances, human body " dragon " (being equivalent to wind, gas), " red bar " (refer to gallbladder, fire, the root that causes all heat symptom-complex diseases), " Baconic " (refer to water, soil, the root that causes all sympotoms caused by cold factors diseases) " three categories of etiologic factors " in poised state, could keep the normal operation of body function.The pathogenic factor of diabetes is because serious unbalance appears in human body " three categories of etiologic factors ", conventionally comparatively significant performance is that " red bar " and " dragon " are contained partially, " Baconic " is on the weak side, cause seven large cereal nutrients of human body (precise and tiny, blood, muscle, fat, skeleton, marrow, seminal fluid) can not normally decompose, excretion and conveying, dirty thing in blood is assembled too much, the vitals function that causes the human bodies such as heart kidney is impaired, show as clinically xerostomia easily hungry, urine urgency-frequency, weak dreaminess, the symptom such as become thin, simultaneously with heating, visual deterioration, the symptoms such as skin pruritus.Tibetan medicine, by conditioning, balance " three categories of etiologic factors ", reaches and falls " red bar " and " dragon ", and righting " Baconic " is object, make the large cereal nutrient of seven in body be decomposed normally and drain, reduce harmful composition in blood, make pancreas obtain nutrition, islet function progressively recovers; Regulate dietary simultaneously, the custom of making the life better, finally reach nutrition pancreas, reduce blood glucose, improve complication, improve the object of patient live and work quality.
There is tight demand in the Tibetan medicinal preparation that therefore, people better treat diabetes to curative effect.Up to now, also do not find any report about Tibetan medicinal composition of the present invention and preparation method thereof.The inventor, through research repeatedly, and by the checking repeatedly of animal and clinical trial, has finally found the Tibetan medicine oral drugs that have the treatment of better curative effect diabetes, thereby has completed the present invention.
Summary of the invention
The object of the invention is just to provide a kind of Tibetan medicine of more effectively treating diabetes.
The present invention is a kind of Tibetan medicine, is to be made or be made up of active component and pharmaceutically acceptable adjuvant by active component, and wherein said active component is to be made up of following bulk drugs: Fructus Malvae, Fructus Coriandri sativi, seed of Herba Apii graveolentis, Fructus Phyllanthi.
It has selected Fructus Malvae, Fructus Coriandri sativi, seed of Herba Apii graveolentis, Fructus Phyllanthi to combine as crude drug, and wherein (1) Fructus Malvae is the dry mature fruit of Malvaceae plant Semen Abutili Malva verticillata L..There is inducing diuresis for treating stranguria syndrome, clearing heat for detumescence, kidney tonifying, the effect of quenching the thirst.For urine retention, gonorrhea, edema, thirsty, kidney-heat, bladder heat.(2) Fructus Coriandri sativi is the dry mature fruit of samphire coriander Coriandrum sativum L..There is heat clearing away, induce sweat, effect of stomach invigorating.For " Baconic wood cloth " disease, dyspepsia, inappetence, thirsty etc.(3) seed of Herba Apii graveolentis is the dry fruit of samphire Herba Apii graveolentis Apium graveolens L..There is clearing heat to ease the stomach, reduce phlegm and wash worm, effect of promoting the production of body fluid to quench thirst.For Baconic's disease, pathogenic heat in the stomach phlegm syndrome, purple phlegm syndrome, xerostomia wish drink.(4) Fructus Phyllanthi is the dry mature fruit of euphorbia plant Fructus Phyllanthi Phyllanthusemblica L..There is clearing away heat and cooling blood, the function of promoting digestion and invigorating the stomach.For heat in blood blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, xerostomia.There is anti-myocardial necrosis and blood fat reducing, antimutagenic, antibacterial, the pharmacological actions such as antioxidation; The clinical hypertension that is used for the treatment of, hepatitis B, chronic pharyngitis, slow down aging etc., have good adjusting blood fat effect to diabetics.Make each efficacy of drugs produce synergism these drug regimens, thereby can effectively treat atrophic gastritis.
The consumption of Tibetan medicine active component of the present invention is also groped in a large number to sum up through inventor and is drawn, each crude drug consumption for all having good therapeutic effect within the scope of following concrete weight proportion:
Fructus Malvae 25～75g, Fructus Coriandri sativi 25～75g, seed of Herba Apii graveolentis 12.5～37.5g, Fructus Phyllanthi 12.5～37.5g.
Be preferably: Fructus Malvae 40～60g, Fructus Coriandri sativi 40～60g, seed of Herba Apii graveolentis 20～30g, Fructus Phyllanthi 20～30g.
More preferably: Fructus Malvae 50g, Fructus Coriandri sativi 50g, seed of Herba Apii graveolentis 25g, Fructus Phyllanthi 25g.
The preparation of Tibetan medicine active component of the present invention can be that direct the crude drug of above-mentioned consumption co-grinding is made; The conventional method that also crude drug of above-mentioned consumption can be adopted to Chinese medicine preparation makes as decoction and alcohol sedimentation technique or ethanol extract from water precipitation (referring to Cao Chunlin chief editor's " pharmaceutics of Chinese drugs " 73rd～74 pages, Science and Technology of Shanghai publishing house publishes in November, 1986).
The active component of Tibetan medicine of the present invention can add various conventional adjuvant required while preparing different dosage form, if disintegrating agent, lubricant, binding agent etc. are with conventional method of Chinese medicinal (" pharmaceutics of Chinese drugs " edited referring to Cao Chunlin, Science and Technology of Shanghai publishing house publishes in November, 1986) be prepared into any conventional peroral dosage form, as powder, pill, capsule, granule, tablet etc.
Tibetan medicine of the present invention has nourishing kidney-YIN, supplementing QI for promoting the production of body fluid, the effect of quenching the thirst.For type of deficiency of both QI and YIN diabetes, disease is seen: thirst and liking drink, polyuria, polyorexia, become thin, fatigue and asthenia, the lazy speech etc. of breathing hard.
The usage and dosage of Tibetan medicine of the present invention is: oral; A 1～1.5g, 1～3 time on the one.
[detailed description of the invention]
Carry out by the following examples further to set forth the preparation method of Tibetan medicine of the present invention.
The preparation of [embodiment 1] Tibetan medicine powder of the present invention:
Take Fructus Malvae 50g, Fructus Coriandri sativi 50g, seed of Herba Apii graveolentis 25g, Fructus Phyllanthi 25g, be jointly ground into fine powder after mixing, mix, subpackage, obtains powder.
The preparation of [embodiment 2] Tibetan medicine pill of the present invention:
Take Fructus Malvae 25g, Fructus Coriandri sativi 25g, seed of Herba Apii graveolentis 12.5g, Fructus Phyllanthi 12.5g, after mixing, be jointly ground into fine powder, mix, with water pill, 60 DEG C of following being dried, polishing, packaging, obtains pill.
The preparation of [embodiment 3] Tibetan medicine granule of the present invention:
Take Fructus Malvae 75g, Fructus Coriandri sativi 75g, seed of Herba Apii graveolentis 37.5g, Fructus Phyllanthi 37.5g, after mixing, be jointly ground into fine powder, mix, add adjuvant granulation, 60 DEG C of following being dried, granulate, subpackage, obtains granule.
The preparation of [embodiment 4] Tibetan medicine capsule of the present invention:
Take Fructus Malvae 40g, Fructus Coriandri sativi 40g, seed of Herba Apii graveolentis 20g, Fructus Phyllanthi 20g, be jointly ground into fine powder after mixing, mix, pack gelatine capsule into, subpackage, obtains capsule.
The preparation of [embodiment 5] Tibetan medicine tablet of the present invention:
Take Fructus Malvae 60g, Fructus Coriandri sativi 60g, seed of Herba Apii graveolentis 30g, Fructus Phyllanthi 30g, after mixing, be jointly ground into fine powder, mix, add adjuvant granulation, 60 DEG C of following being dried, granulate, tabletting, subpackage, obtains tablet.
Further set forth below the beneficial effect of Tibetan medicine of the present invention by test example, these test examples have comprised pharmacodynamics test and the clinical observation on the therapeutic effect test of Tibetan medicine embodiment 1 powder of the present invention.
On normal animal blood glucose, spontaneous hyperglycemia and serum insulin, impact, the streptozotocin on mouse blood sugar brings out the pharmacodynamics test of the impact of hyperglycemic rat blood glucose value and glycolated hemoglobin to [test example 1] Tibetan medicine embodiment 1 powder of the present invention:
Test material: anthology invention Tibetan medicine embodiment 1 powder; Glibenclamide tablet (Glibenclamide Tablets), 2.5mg/ sheet, lot number: 20100513, Shoutou Jinshi General Pharmaceutical Factory produces; Acarbose sheet: Beijing Bayer medicine health Co., Ltd (lot number: 201000704); Mount Tai I-insulin radioimmunoassay, RIA medicine box, Isotope Research institute of China Atomic Energy Science Research Institute.Streptozotocin: Sigma company produces, glycolated hemoglobin test kit (microtrabeculae method): Ci Cheng biochemical reagents factory of Ningbo City; NIH mice, weight 18～22g; NOD mice, weight 25～35g; SD rat, weight 180～220g, male and female half and half, are provided by animal housing of Part of Qinghai Plateau biological study institute.
1, the impact of Tibetan medicine embodiment 1 powder of the present invention on normal animal blood glucose:
Experimental technique: NIH mice, 50, male and female half and half, after 6h, measure blood glucose on an empty stomach, are divided at random 5 groups according to blood glucose value and Animal Sex equilibrium, and gavage gives following medicine respectively: Normal group (distilled water); Glyburide group (25mg/kg); Tibetan medicine embodiment 1 powder of the present invention is pressed the basic, normal, high dosage group of crude drug (2,4,8mg/kg).Successive administration 7d, administration volume is pressed 20ml/kg, empty stomach 6h before administration in the 7th day, after administration, 1h animal is got blood, by blood glucose meter mensuration animal blood glucose value.Experimental result is in table 1.
The impact of table 1 Tibetan medicine embodiment 1 powder of the present invention on normal mouse blood sugar value (x ± s)
Blood glucose value (mmol/L) after blood glucose value (mmol/L) medicine before group number of animals dosage (crude drug g/kg) medicine
Normal group 10 4.69 ± 0.78 4.65 ± 0.83
Glyburide 10 25mg 4.73 ± 1.24 3.73 ± 0.69
*
Low dose group 10 2 4.71 ± 0.83 4.47 ± 1.23
Middle dosage group 10 4 4.75 ± 0.79 4.54 ± 0.87
High dose group 10 8 4.73 ± 0.82 4.55 ± 0.96
Note: with Normal group comparison
*p<0.01.
Experimental result: the basic, normal, high dosage group of Tibetan medicine embodiment 1 powder of the present invention has no significant effect normal mouse blood sugar.
2, Tibetan medicine embodiment 1 powder of the present invention impact on mouse blood sugar on the impact of spontaneous hyperglycemia and serum insulin:
Experimental technique: NOD mice, on an empty stomach, after 6h, measure blood glucose, select blood glucose value higher than 50 of the animals of 11.1mmol/L, be divided at random 5 groups, gavage gives following medicine respectively: matched group (distilled water); Glyburide group (25mg/kg); Tibetan medicine embodiment 1 powder of the present invention is pressed the basic, normal, high dosage group of crude drug (2,4,8mg/kg).Successive administration 14d, measures animal blood glucose value by blood glucose meter, uses serum measured by radioimmunoassay insulin, the results are shown in Table 2,3.
(x scholar s) on the impact of spontaneous hyperglycemia mouse blood sugar for table 2 Tibetan medicine embodiment 1 powder of the present invention
Blood glucose value (mmol/L) after blood glucose value (mmol/L) medicine before group number of animals dosage (crude drug g/kg) medicine
Model control group 10 13.23 ± 22.38 13.86 ± 1.65
Glyburide 10 25mg 13.37 ± 2.58 10.47 ± 2.18
*
Low dose group 10 2 13.51 ± 1.72 12.23 ± 1.28
*
Middle dosage group 10 4 13.54 ± 1.76 11.29 ± 1.56
*
High dose group 10 8 13.45 ± 2.18 10.84 ± 1.43
*
Note: with model control group comparison
*p<0.05,
*p<0.0l.
The impact of table 3 Tibetan medicine embodiment 1 powder of the present invention on spontaneous hyperglycemia mice serum insulin (x ± s)
Group number of animals dosage (crude drug g/kg) serum insulin (MIU/L)
Model control group 10 14.92 ± 4.43
Glyburide 10 25mg 26.61 ± 1.76
*
Low dose group 10 2 15.38 ± 2.37
Middle dosage group 10 4 19.69 ± 5.24
*
High dose group 10 8 26.31 ± 3.78
*
Note: with model control group comparison
*p<0.05,
*p<0.0l.
Experimental result: the basic, normal, high dosage group of oral Tibetan medicine embodiment 1 powder of the present invention of NOD mice, can reduce blood glucose and rising serum insulin.
3, Tibetan medicine embodiment 1 powder of the present invention brings out the impact of hyperglycemic rat blood glucose value and glycolated hemoglobin on streptozotocin:
Impact on rat blood sugar and glycolated hemoglobin: experimental technique: SD rat, fasting be can't help after water 24 h, low dose of intravenous injection streptozotocin 25mg/kg, 1 time/week, add high heat forage feed simultaneously and bring out type Ⅱdiabetes mellitus, after the 2nd injection, l week is measured blood glucose, and 50 of the rats of selection fasting glucose >=7.8mmol/L, test.Be divided at random 5 groups, 10 every group, give respectively following medicine: hyperglycemia model group (distilled water); Acarbose group (25mg/kg); Tibetan medicine embodiment 1 powder of the present invention is pressed the basic, normal, high dosage group of crude drug (1,2,4mg/kg).Separately establish 10 of normal control rats (gavage equal-volume distilled water).Give Experimental agents by above dosage gavage, 14d continuously, empty stomach 12 h before 14d administration, after last administration, 1h measures blood glucose and glycolated hemoglobin.Experimental result is in table 4,5.
Table 4 Tibetan medicine embodiment 1 powder of the present invention brings out the impact (x ± s) of hyperglycemic rat blood glucose on streptozotocin
Blood glucose value (mmol/L) after blood glucose value (mmol/L) medicine before group number of animals dosage (crude drug g/kg) medicine
Normal group 10 4.45 ± 0.78 4.63 ± 0.82
Model group 10 9.27 ± 1.23 9.43 ± 1.27
△ △
Acarbose 10 25mg 9.24 ± 1.82 6.31 ± 1.32
*
Low dose group 10 1 9.31 ± 1.26 8.52 ± 1.26
Middle dosage group 10 2 9.35 ± 1.28 8.18 ± 0.79
*
High dose group 10 4 9.27 ± 1.39 7.73 ± 1.24
*
Note: with Normal group comparison
△ △p<0.01;
With model group comparison
*p<0.05,
*p<0.0l.
Table 5 Tibetan medicine embodiment 1 powder of the present invention brings out the impact (x ± s) of hyperglycemic rat glycolated hemoglobin on streptozotocin
Group number of animals dosage (crude drug g/kg) glycolated hemoglobin (%)
Normal group 10 4.56 ± 1.42
Model group 10 9.12 ± 1.25
△ △
Acarbose 10 25mg 7.05 ± 1.12
*
Low dose group 10 1 8.51 ± 1.39
Middle dosage group 10 2 8.16 ± 1.83
*
High dose group 10 4 7.14 ± 0.26
*
Note: with Normal group comparison
△ △p<0.01;
With model group comparison
*p<0.05,
*p<0.01.
Impact on blood glucose after Oral Administration in Rats sucrose: experimental technique: the same, give trial drug by above dosage gavage, 14d continuously, empty stomach 6h before administration in the 14th day, by above dosed administration time, in medicine, contain sucrose 0.125g/ml, administration volume is by 20 ml/kg.With blood glucose meter measure to after sucrose 0.5,1,2h blood glucose value.Experimental result is in table 6.
Table 6 Tibetan medicine embodiment 1 powder of the present invention on Oral Administration in Rats sucrose after the impact (x ± s) of blood glucose
Group number of animals dosage blood sugar content (mmol/L)
(crude drug g/kg) 0h 0.5h 1h 2h
Normal group 10 4.66 ± 0.89 8.45 ± 0.79 8.08 ± 0.74 5.34 ± 0.81
Model control group 10 9.31 ± 1.23
△ △15.87 ± 1.83
△15.75 ± 1.52
△ △13.37 ± 1.56
△ △
Acarbose 10 25mg 8.37 ± 1.34 12.86 ± 1.48
*13.11 ± 1.38
*11.40 ± 1.23
*
Low dose group 10 1
8.53 ± 1.12 14.12 ± 1.29
*13.63 ± 1.24
*11.75 ± 1.21
*
Middle dosage group 10 2
8.29 ± 0.14
*13.26 ± 1.51
*13.37 ± 1.47
*11.48 ± 1.48
*
High dose group 10 4
7.72 ± 1.38
*12.15 ± 1.36
*12.18 ± 1.31
*10.51 ± 1.57
*
Note: with Normal group comparison
△p<0.05
△ △p<0.01; With model group comparison
*p<0.05
*p<0.01.
Experimental result: the hyperglycemic rat that Tibetan medicine embodiment 1 powder of the present invention rises the mould index of chain urea, after oral administration, has the effect that reduces blood glucose and glycolated hemoglobin.And blood sugar increasing time and reduce blood glucose peak concentration after deferrable Oral Administration in Rats sucrose.
Experimental result shows, Tibetan medicine embodiment 1 powder of the present invention has no significant effect normal mouse blood sugar, but the blood sugar increasing time after deferrable Oral Administration in Rats sucrose, can reduce spontaneous hyperglycemia and rising serum insulin, can reduce blood glucose and glycolated hemoglobin that streptozotocin brings out hyperglycemic rat, therefore Tibetan medicine embodiment 1 powder of the present invention has positive impetus at Tibetan medicine to the treatment field of diabetes.
[test example 2] Tibetan medicine embodiment 1 powder treatment diabetes clinical observation on the therapeutic effect of the present invention:
Physical data: my institute's application Tibetan medicine embodiment 1 powder treatment Diabetes Clinic and inpatient 124 examples of the present invention, all data is divided into treatment group and matched group, treatment group 68 examples, wherein male 44 examples, female's 24 examples at random.40～50 years old age, 16 examples, 50～60 years old 38 example, 61 years old person's 14 example of >.Companion's coronary heart disease 6 examples, cerebrovascular disease 7 examples, Peripheral neuropathy 4 examples.Matched group 56 examples, male 32 examples, female's 24 examples.40～50 years old age, 14 examples, 50～60 years old 32 example, >60 year 10 examples.Wherein accompany coronary disease patient 7 examples, cerebrovascular disease 5 examples, Peripheral neuropathy person 3 examples.The average 12.8mmol/L for the treatment of group fasting glucose, glucose in urine (+++), matched group fasting glucose meansigma methods is 13.3mmol/L.Two groups of patients all have three-many-one-little symptom, meet the diagnostic criteria of traditional Chinese medical science diabetes.Western medicine diagnose meets the diabetes diagnosis standard of WHO formulation in 1999, and confirms as type 2 diabetes mellitus.
Therapeutic Method: treatment group: adopt Tibetan medicine embodiment 1 powder of the present invention, a 1.5g, 1～3 time on the one.It within 30 days, is a course for the treatment of.
Matched group: oral diabetes pill, LIUWEI DIHUANG WAN, to keep on a diet, the course for the treatment of is the same.Observe treatment two groups of clinical symptoms of fore-and-aft observing and sign, fasting glucose, blood fat, hemorheology index.
Clinical efficacy evaluation criteria: effective: transference cure, below fasting glucose 6.Ommol/L, the 6.8mmol/L that on average declines, glucose in urine (); Effective: transference cure, fasting glucose 8.Ommol/L, glucose in urine (++); Invalid: symptom makes moderate progress, fasting glucose >8mmol/L, glucose in urine (++).Effective adding, effectively adds up to total effective rate.
Table 7 liang group patient clinical curative effect comparison
The effective enabledisable total effective rate of group number of cases
Treatment group 68 43(63.24%) 16(23.53%) 9(13.23%) 86.77%
Matched group 56 29(51.79%) 17(30.36%) 10(17.85%) 82.15%
A table 8 liang group fasting glucose changes situation (mmol/L)
Group number of cases fasting glucose P value
Front 12.81 <0.01 for the treatment of group 68 treatment
Treatment rear 6.28
Front 13.17 <0.01 of matched group 56 treatment
Treatment rear 7.64
Before and after table 9 liang group treatment, blood fat changes situation (M ± SD)
Group number of cases cholesterol triglyceride beta Lipoprotein
Treatment group 68 treatments front 7.58 ± 1.26 2.64 ± 0.71 6.53 ± 1.17
Treatment rear 6.15 ± 1.17 2.12 ± 0.85 5.14 ± 1.24
Matched group 56 treatments front 7.46 ± 1.15 2.57 ± 0.61 6.49 ± 1.26
Treatment rear 6.35 ± 1.29 2.16 ± 0.72 5.63 ± 1.33
Note: with the front relatively P<0.05 for the treatment of.
Before and after table 10 liang group treatment, hemorheology sexually revises situation (M ± SD)
Group number of cases hematocrit whole blood specific viscosity blood plasma specific viscosity
Treatment group 68 treatments front 44.3 ± 5.5 5.28 ± 0.68 1.79 ± 0.19
Treatment rear 40.6 ± 3.2 4.36 ± 0.43 1.73 ± 0.15
Matched group 56 treatments front 44.1 ± 4.8 5.11 ± 0.57 1.77 ± 0.14
Treatment rear 42.2 ± 4.6 4.78 ± 0.56 1.74 ± 0.17
Note: with the front relatively P<0.05 for the treatment of.
Clinical observation result: apply Tibetan medicine embodiment 1 powder treatment diabetes type II patient 68 examples of the present invention, effective 43 examples, effective 16 examples, total effective rate 86.77%, matched group is observed 56 examples equally, effective 29 examples, effective 17 examples, total effective rate be 82.15%, two group obvious to diabetics blood sugar lowering curative effect, but no significant difference (P<0.05).In two groups of therapeutic processes, all do not occur untoward reaction, clinical observation result shows: Tibetan medicine embodiment 1 powder treatment diabetes curative effect of the present invention is definite, and clinic is promoted the use of, and has good application prospect.
In the preparation of conventional oral solid formulation dosage form, the preparation of powder belongs to part operation above in other conventional oral solid formulation preparation process, the test example of powder has proved, having good effect aspect treatment diabetes, also just to have illustrated that pill, granule, capsule, the tablet in conventional oral solid formulation dosage form also has same effect; Be that the above-mentioned embodiment enumerating 1-5 has same effect.Illustrate that Tibetan medicine of the present invention has good effect aspect treatment diabetes.
Claims (5)
1. treat the Tibetan medicine of diabetes for one kind, it is characterized in that it is to be made or be made up of active component and pharmaceutically acceptable adjuvant by active component, wherein said active component is to be made up of the crude drug of following concrete weight proportion: Fructus Malvae 25～75g, Fructus Coriandri sativi 25～75g, seed of Herba Apii graveolentis 12.5～37.5g, Fructus Phyllanthi 12.5～37.5g.
2. Tibetan medicine according to claim 1, wherein said active component is to be made up of the crude drug of following concrete weight proportion: Fructus Malvae 40～60g, Fructus Coriandri sativi 40～60g, seed of Herba Apii graveolentis 20～30g, Fructus Phyllanthi 20～30g.
3. Tibetan medicine according to claim 2, wherein said active component is to be made up of the crude drug of following concrete weight: Fructus Malvae 50g, Fructus Coriandri sativi 50g, seed of Herba Apii graveolentis 25g, Fructus Phyllanthi 25g.
4. according to any one Tibetan medicine described in claim 1-3, it is peroral dosage form.
5. Tibetan medicine according to claim 4, it is powder, pill, granule, capsule or tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410222945.8A CN103961392B (en) | 2014-05-25 | 2014-05-25 | Traditional Tibetan medicine for treating diabetes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410222945.8A CN103961392B (en) | 2014-05-25 | 2014-05-25 | Traditional Tibetan medicine for treating diabetes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103961392A true CN103961392A (en) | 2014-08-06 |
| CN103961392B CN103961392B (en) | 2017-02-01 |
Family
ID=51231714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410222945.8A Active CN103961392B (en) | 2014-05-25 | 2014-05-25 | Traditional Tibetan medicine for treating diabetes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103961392B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700397A (en) * | 2009-11-10 | 2010-05-05 | 尼玛次仁 | Tibetan medicine composite for treating diabetes and preparation method of preparation thereof |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
| JP2013209351A (en) * | 2012-03-30 | 2013-10-10 | Sunstar Inc | Antioxidant function enhancer |
-
2014
- 2014-05-25 CN CN201410222945.8A patent/CN103961392B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101700397A (en) * | 2009-11-10 | 2010-05-05 | 尼玛次仁 | Tibetan medicine composite for treating diabetes and preparation method of preparation thereof |
| CN101708295A (en) * | 2009-12-04 | 2010-05-19 | 卢速江 | Chinese medicinal preparation for treating diabetes and preparation methods thereof |
| JP2013209351A (en) * | 2012-03-30 | 2013-10-10 | Sunstar Inc | Antioxidant function enhancer |
Non-Patent Citations (4)
| Title |
|---|
| 国家中医药管理局《中华本草》编委会编著: "《中华本草 蒙药卷》", 30 September 2004, 上海科学技术出版社 * |
| 朗杰卓嘎: "糖尿病与藏医", 《西藏研究》 * |
| 王高娃: "糖尿病的藏蒙医文献研究", 《中国民族医药杂志》 * |
| 韩刚等: "余甘子提取物对糖尿病小鼠血糖的影响", 《食品科学》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103961392B (en) | 2017-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104688822A (en) | Tablet for assisting to reduce blood glucose and preparation method | |
| CN105079447A (en) | Health care product or medicine composition capable of relieving fatigue and enhancing immunity | |
| CN104940479A (en) | TCM composition for treating AD diseases | |
| CN102551046B (en) | Natural health composition for weight reduction and application of same | |
| CN106214964A (en) | Traditional Chinese medicine for soothing nerves preparation | |
| CN104388236A (en) | Grape wine as well as preparation method and application thereof | |
| CN100374140C (en) | Health-care for diabetes | |
| CN107006856A (en) | One kind enhancing endurance, raising anti anoxia tolerance nutritional agents and preparation method thereof | |
| CN117018125B (en) | Anti-fatigue pharmaceutical composition | |
| CN102134550B (en) | Health-care tonic wine and preparation process thereof | |
| CN103948666B (en) | Preparation method of Tibetan medicine for treating diabetes | |
| CN102106538A (en) | Healthcare product prepared from rhodiola root, spirulina and notoginseng | |
| CN100345566C (en) | Medicine composition used for reducing weight, prepn. method and use thereof | |
| CN103520330B (en) | A kind of veterinary dispersible tablet and its production and use | |
| CN102784230A (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| CN103961392B (en) | Traditional Tibetan medicine for treating diabetes | |
| CN103211996A (en) | Preparation method of traditional Chinese medicine for treating diabetes mellitus | |
| CN103393938B (en) | Traditional Chinese medicine composition for reducing blood sugar | |
| CN102552677B (en) | Coptis chinensis and radix rehmanniae Anxiao capsule and preparation method thereof | |
| CN102366480B (en) | Medicine for treating diabetes and preparation method thereof | |
| CN102949681B (en) | Composition for preventing or treating colds, and its preparation method | |
| CN103961551A (en) | Traditional Tibetan medicine for treating diabetes | |
| CN104013853B (en) | A kind of composition of strong kidney kidney tonifying and preparation method thereof | |
| CN102274428A (en) | Pharmaceutical composition with effect on treating irritable bowel syndrome and preparation method and application thereof | |
| CN101979084B (en) | Chinese medicinal composition for warming kidney and tonifying yang and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |